EUCTR2020-004535-24-NL招募中1 期
A First-in-Human Study of Highly Selective FGFR2 inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors - First-in-Human Study of RLY-4008 in patients with ICC and other advanced solid tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Main inclusion criteria for the study, including specific criteria for Part 1, 2 and 3 can be found in the study protocol (section 5.2).
- •14. Patient is currently receiving RLY-4008 on RLY-4008-101 Study and benefiting from treatment as assessed by the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 363
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 187
排除标准
- •Main exclusion criteria for the study, including specific criteria for Part 1, 2 and 3 can be found in the study protocol (section 5.3).
- •21. Patient has permanently discontinued treatment with RLY-4008 for any reason before enrolling into Part 4.
研究者
相似试验
招募中
1 期
A study to investigate the effects of study drug RLY-4008 in patients with Intrahepatic Cholangiocarcinoma and other Advanced Solid TumorsEUCTR2020-004535-24-SERelay Therapeutics, Inc.550
招募中
不适用
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid TumorsBile Duct CancerIntrahepatic Bile Duct Carcinoma10019815NL-OMON54283Relay Therapeutics, Inc.4
招募中
1 期
A study to investigate the effects of study drug RLY-4008 in patients with Intrahepatic Cholangiocarcinoma and other Advanced Solid TumorsEUCTR2020-004535-24-DERelay Therapeutics, Inc.550
进行中（未招募）
1 期
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid TumorsFGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/RearrangementFGFR2 Gene TranslocationFGFR2 Gene ActivationOther Solid Tumors, AdultCholangiocarcinomaIntrahepatic CholangiocarcinomaNCT04526106Elevar Therapeutics540
终止
1 期
A Phase 1/2 study to determine the effect of Doxorubicin loaded EnGeneIC Delivery Vehicles on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma MultiformeCancer - BrainACTRN12613000297729EnGeneIC Ltd46